Toll-like Receptor: Breast Cancer Development and Immunotherapy

  • Manna E
N/ACitations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Breast cancer is well known leading causes of mortality in the females. Current studies have suggested that the imbalances in inflammatory and immune-associated proteins may also give rise to breast cancer and disease progression. Toll like receptors (TLRs) are essential components of innate immune system that protect the host against bacterial and viral infection. It not only express in innate immune cell, its expression also found in breast cancer cells. Activation of TLRs leads to the activation of inflammatory pathways. Recent reports provide such evidences, which suggest the important role of TLRs in breast cancer pathogenesis and recurrence. TLRs are not only involved in cancer development, but also involve in anticancer immunotherapy. There are some agonists and antagonist of TLRs, used in anticancer immunotherapy, is targeted in clinic successfully.

Cite

CITATION STYLE

APA

Manna, E. (2016). Toll-like Receptor: Breast Cancer Development and Immunotherapy. Archives in Cancer Research, 4(3). https://doi.org/10.21767/2254-6081.100099

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free